Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine (MSC) and L SeMet in Adult Males
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Selenomethionine (Primary) ; Selenomethylselenocysteine (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 26 Nov 2014 Biomarkers information updated
- 02 May 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 02 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.